台灣臨床試驗主持人資料庫|TPIDB

2018-03-01 - 2022-12-13

Phase III

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Condition/Disease

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Test Drug

Nivolumab

Participate Sites
7Sites

Not yet recruiting1Sites

Terminated3Sites

謝清昀

China Medical University Hospital-Taipei

未分科

2018-12-18 - 2021-12-31

Phase I

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Condition/Disease

Advanced Solid Tumors
Test Drug

ASP8374(PTZ-201)

Participate Sites
4Sites

Recruiting3Sites

邱昌芳

China Medical University Hospital-Taipei

未分科

2017-01-06 - 2022-01-05

Phase III

ONO-4538 Phase III Study A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

Condition/Disease

Gastric Cancer
Test Drug

Nivolumab

Participate Sites
10Sites

Terminated8Sites

白禮源

China Medical University Hospital-Taipei

未分科

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2016-05-02 - 2021-05-12

Phase III

A Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults who require regular red blood cell transfusions due to beta (β)-thalassemia

Condition/Disease

beta (β)-thalassemia
Test Drug

Luspatercept (ACE-536)

Participate Sites
5Sites

Terminated4Sites

彭慶添

China Medical University Hospital-Taipei

未分科

2015-09-01 - 2018-07-31

Phase II

A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus

Condition/Disease

Systemic Lupus Erythematosus (SLE)
Test Drug

ALX-0061

Participate Sites
7Sites

Terminated5Sites

黃春明

China Medical University Hospital-Taipei

未分科

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

Condition/Disease

Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2
Test Drug

Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元

China Medical University Hospital-Taipei

未分科

朱啟仁

Taipei Veterans General Hospital

2017-10-01 - 2023-05-31

Phase III

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)

Condition/Disease

Stage IV, Metastatic Non-small Cell Lung Cancer
Test Drug

Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿

China Medical University Hospital-Taipei

未分科

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-10-15 - 2021-06-11

Phase II

A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

Condition/Disease

Metastatic Non-Small Cell Lung Cancer
Test Drug

Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

夏德椿

China Medical University Hospital-Taipei

未分科

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-08-07 - 2021-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

Condition/Disease

Extensive Stage Small Cell Lung Cancer
Test Drug

Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿

China Medical University Hospital-Taipei

未分科

陳育民

Taipei Veterans General Hospital

Division of Thoracic Medicine

2015-03-01 - 2019-06-30

Phase II/III

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial

Condition/Disease

Chronic Hepatitis C
Test Drug

MK-5172A

Participate Sites
10Sites

Terminated7Sites

Study ended1Sites

彭成元

China Medical University Hospital-Taipei

未分科

彭成元

China Medical University Hospital

Digestive System Department

Search Result

List